Advances in research and technology now afford us the unique opportunity to develop and test novel diagnostics and therapeutics. This conference takes advantage of the collective experience and expertise of our speakers in drug discovery. A broad range of policy, research, and venture topics are covered.

Advances in research and technology now afford us the unique opportunity to develop and test novel diagnostics and therapeutics. This conference takes advantage of the collective experience and expertise of our speakers in drug discovery. A broad range of policy, research, and venture topics are covered.

ENDO 2019 – ENDOCRINE SOCIETY ANNUAL MEETING

Each year, ENDO brings together leading experts, researchers, and clinicians in the field for the most valued and well attended translational endocrinology meeting in the world. ENDO represents a convergence of science and practice that not only highlights but also facilitates breakthrough discoveries in the field of endocrinology.

ENDO is a can't miss experience with an extensive program featuring cutting-edge science, poster sessions, basic science pathways, the newest products and technologies at the ENDOExpo, and more.

ENDO 2019 was held at the Ernest N. Morial Convention Center in New Orleans, LA, from March 23-26, 2019 and brought together 7,500 attendees from around the world.

Advances in research and technology now afford us the unique opportunity to develop and test novel diagnostics and therapeutics. This conference takes advantage of the collective experience and expertise of our speakers in drug discovery. A broad range of policy, research, and venture topics are covered.

Genomic variation is a driving force of animal and human health, and susceptibility to disease. Yet our knowledge rarely spans human ethnic genomic diversity and genomic variation between animal breeds, limiting their translational impact. This symposium aims to: 1) Highlight translational genomics in humans and animals (clinical medicine and animal breeding for health and productivity; 2) Explore synergies and cross-disciplinary learning; 3) Explore opportunities to leverage genomic diversity to push the current boundaries to translation; and 4) Address translation and affordability in low- and middle-income settings. Large-scale genomics initiatives like Genome England, the US Precision Medicine initiative, and the Human Heredity and Health in African Consortium are providing extraordinarily large data sets to explore useful genotype-phenotype connections. Equivalent initiatives for animal data are starting. This meeting will explore the translation of genomic research in animals and humans, high and low-resourced environments, ethnic diversity, and cultural context. Identifying common strands in animal and human health opens up opportunities for repurposing of ideas and applications, and for finding innovative solutions for translational genomics through cross-boundary communities of practice.

Emerging and re-emerging viruses have the potential to cause high morbidity and mortality and range from localized outbreaks to epidemics. Due to their emerging nature, most aspects of the biology and infectious potential of these viruses are poorly understood. Our continuing struggle to respond to a procession of pandemics including SARS, avian influenza, MERS, Ebola and more recently Zika, highlights key gaps in our knowledge and should serve to motivate our re-thinking on how we can better prepare and deal with future unknown viral threats. This meeting will focus on important areas such as surveillance, diagnostics and countermeasures and other important advances in new technologies and how they are being applied to research. Furthermore, we will discuss how to facilitate the translation of research, data and candidate treatments through the development pipeline in a timely and cost-effective manner. The key themes to be covered include the need to understand why zoonotic diseases matter, their association with agriculture, the importance of surveillance and early detection, and the difficulties of dealing with diseases that involve both medical and veterinary communities. The conference will bring together experts in virology, immunology, vaccinology, epidemiology with those that seek to transfer knowledge between these groups, veterinarians and industry and government. Further, this meeting would bring together individuals involved in the control of these diseases in government and non-government organizations, as well as people involved in study of zoonosis and countermeasures. The creation of global networks and sharing of information will ensure that we are better prepared for future outbreaks.

Bacteria and fungi residing in the female genital tract have been associated with elevated risks of HIV acquisition and transmission, pelvic inflammatory disease, miscarriage, preterm birth, and invasive maternal and neonatal infections. The increased availability of high-throughput genomic testing since the turn of the century has revealed a more detailed picture of these organisms than was possible when evaluation depended on microscopy and culture. The interrelationships between sexually transmitted infections, vaginal dysbiosis, vulvovaginal candidiasis, and vaginal pathobiont carriage are being elucidated, and their effects on the cervicovaginal mucosal barrier and immune system are being characterized. The mechanisms that may lead to adverse outcomes are being unraveled, and an increasing number of interventions are in clinical trials. In this meeting, the current understanding of female and male genital tract microbiology and immunology, including functional microbiology and biofilms, will be presented and knowledge gaps identified. Potential mechanisms leading to adverse outcomes, and a variety of potential prevention and/or treatment interventions, will be presented and discussed. The exponential progress made in recent years will hopefully lead to efficacious public health interventions to reduce the high prevalence of adverse sexual and reproductive health outcomes in women, especially in resource-poor settings.

Progress made in human genetics has revealed increasingly more disease-associated genes for Alzheimer's disease (AD), Parkinson's disease (PD), frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS) and other neurodegenerative disorders. These discoveries have linked neurodegenerative diseases with several common key biological processes that now need further study. At the same time, tremendous strides have been made in microglial research, revealing unexpected results that challenge the traditional view of microglia as simply scavengers of the diseased CNS. The aims to conferences on "Advances in Neurodegenerative Disease Research and Therapy" and "New Frontiers in Neuroinflammation" were to:

• Focus on emerging areas of neurodegenerative disease research including RNA metabolism, protein trafficking and innate immune responses;
• Discuss recent advances in imaging, genetics and immunology, in particular high-throughput sequencing methods, and their implications for microglial biology research;
• Explore the origin and functions of inflammatory glia, the blood brain barrier, myeloid cells and other signaling elements;
• Challenge existing paradigms and provide a platform to cross-fertilize ideas and encourage new collaborations that could lead to novel mechanisms and therapeutic targets for treating neurodegenerative diseases.

Welcome to the Virtual Access Recap website for the 2018 Stanford Drug Discovery Symposium. Through a partnership with Stanford Cardiovascular Institute, Keystone Symposia recorded on video a select number of presentations and discussions from the meeting.  With this partnership, we hope to extend the reach and impact of this event to the broader scientific community.

Mitochondrial dysfunction has emerged as a key factor in a myriad of diseases, including neurodegenerative and metabolic disorders. Likewise, several diseases have been linked to dysfunctional selective autophagy. Protein aggregates and damaged or superfluous organelles such as mitochondria, ER, peroxisomes, endosomes and lysosomes can be degraded by autophagy in a highly selective manner that plays a key role in cellular homeostasis. The aims of the joint Keystone Symposia conferences on "Mitochondrial Biology" and "Selective Autophagy" were to:

• Explore the most up-to-date progress regarding the molecular mechanisms underlying selective autophagy and its link with multiple diseases, including presentations on the autophagic machinery that mediates removal of different types of cargo and dysregulated selective autophagy in diseases, including neurodegenerative and immune diseases;
• Present and discuss cutting-edge results regarding how mitochondrial form and function are controlled at the cellular and organismal levels and how the many functions of mitochondria impinge on health and disease states, including cancer;
• Discuss how new technologies and experimental approaches, such as imaging, will speed progress in the two fields;
• Provide a forum for trainees and junior investigators to learn about current progress and future directions of the field, and to establish discussions and networks with other investigators;
• Stimulate collaborations among scientists in each field, and across the two fields.

By 2025, most patients with cancer will receive immunotherapy as part of their treatment regimen. This symposium will cover the most critical topics integral to this vision: How can we integrate, sequence or combine immunotherapy with standard-of-care cytotoxic therapy, radiotherapy and targeted therapies? Which preclinical models are best predictive of combination approaches? How do we combine immune agonists as well as molecules inhibiting immune-suppressive pathways with checkpoint inhibitors? What are the rational combinations for cancer vaccines and viro-therapy? Which combinatorial approaches could prevent or treat adaptive mechanisms of resistance? Most immunotherapies are being developed in isolation, or being tested as single agents in preclinical models or in clinical studies. This conference helps to address the gaps in knowledge of how and when to combine therapies, and how to integrate immunotherapy into current standard-of-care or novel targeted therapy approaches – both preclinical and clinical. Overall, the objectives of this meeting are to: Elucidate rational combinations for immunotherapy; Discuss preclinical and other models to inform combinatorial approaches; Understand the relevance for biomarker approaches; and Provide insights into the latest preclinical and clinical data for immunotherapy combinations.

To view the program of this conference, visit  www.keystonesymposia.org/18C5

Single cell omics is a new frontier in biology, where genome-wide data is captured at the resolution of individual cells. Single cell high-throughput technologies are being developed in the areas of imaging, mass spectrometry and DNA- and RNA-sequencing, and combinations thereof. The corresponding software and visualization tools are also a large active field of research. Single cell omics has important implications for all areas of development, differentiation and cellular decision-making, because these can now be studied at unprecedented resolution. Equally, single cell omics methods are shedding new light on immunity and cancer, due to the heterogeneous cell populations involved in both areas of biology. Therefore, these approaches are revolutionizing both basic biology as well as our understanding of disease, and technologies involved in translation to medicine. Since the field is in its infancy, and there are few meetings dedicated to this topic, there is a huge unmet need in the community to congregate and exchange ideas and information about new methods and the biological insights gained. A meeting such as this will be of continuing importance until single cell omics technologies become commonplace and established, and integrated into allareas of biology.

This exclusive package of digital content derives from Keystone Symposia’s oversubscribed conference on “Single Cell Omics” that took place May 26-30, 2017 in Stockholm, Sweden and was organized by Drs. Sarah Teichmann, Evan W. Newell and William J. Greenleaf.

To view the program of this conference, visit www.keystonesymposia.org/17E3.

This exclusive package of digital content derives from Keystone Symposia’s oversubscribed conference on “Cancer Immunology and Immunotherapy” that took place March 19-23, 2017 in Whistler, British Columbia, Canada and was organized by Drs. Robert D. Schreiber, James P. Allison, Philip D. Greenberg and Glenn Dranoff. To view the program of this conference, visit www.keystonesymposia.org/17C7.